ClinicalTrials.gg
CompletedNCT00340834TRANSFORMSUpdated Sep 21, 2017Results posted

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

A Phase 3 interventional study of Fingolimod 1.25 mg and Fingolimod 0.5 mg in Multiple Sclerosis, sponsored by Novartis. Completed at 170 sites in 18 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-09-21.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,292
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
4th of 34
1,292 · median 167
Started
2006
with 2 others
Phase 3
12 of 34
1 open now
Registered
3rd of 34
by date
Lead sponsor
10 of 34
Novartis

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 4th largest by enrollment, is one of 3 that started in 2006, is one of 12 in phase 3, and was the 3rd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • FTY720
  • Interferon
  • RRMS
  • Multiple Sclerosis
  • Efficacy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis (MS)
  • Patients with a relapsing-remitting disease course
  • Patients with Expanded Disability Status Scale (EDSS) score of 0-5.5

Exclusion criteria

Exclusion Criteria:

  • Patients with other chronic disease of the immune system, , acute pulmonary disease, cardiac failure, etc
  • Pregnant or nursing women
  • Patients who cannot tolerate treatment with an interferon

Other protocol-defined inclusion/exclusion criteria applied to the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
1,292 participants (actual)

Study arms

  • Experimental
    Fingolimod 1.25 mg

    Drug: Fingolimod 1.25 mg

  • Experimental
    Fingolimod 0.5 mg

    Drug: Fingolimod 0.5 mg

  • Active comparator
    Interferon β-1a 30 µg

    Drug: Interferon β-1a 30 µg

Interventions

  • Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly. Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.

    Also known as: FTY720

  • Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly. Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.

    Also known as: FTY720

  • DrugInterferon β-1a 30 µg

    Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily. Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.

06

What researchers measure

Primary outcomes

  1. Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study

    The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study

    The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.

    Time frame: Baseline to Month 12

  2. Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study

    The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.

    Time frame: Baseline to Month 12

  3. Estimated Annualized Aggregate Relapse Rate (ARR) in the Core and Extension Phases of the Study

    The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.

    Time frame: Month 0 to end of study (up to approximately 4.5 years)

  4. Number of New or Newly Enlarged T2 Lesions in the Extension Phase of the Study

    The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.

    Time frame: Month 12 to end of study (up to approximately 3.5 years)

  5. Percentage of Participants Free of 3-month and 6-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Extension Phase of the Study

    The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.

    Time frame: Baseline to end of study (up to approximately 4.5 years)

07

Results

Posted May 16, 2011

Participant flow

Patients randomized in the Core Phase (CP) to receive 0.5 mg or 1.25 mg fingolimod received the same dose in the Extension Phase (EP). Patients randomized to receive interferon-β-1a in the CP were re-randomized to receive either 0.5 mg or 1.25 mg fingolimod in a 1:1 ratio in the EP. Upon protocol amendment, all patients received 0.5 mg fingolimod.

Core Phase of Study
Participant flow — Core Phase of Study
MilestoneFingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a 30 µgInterferon β-1a/Fingolimod 1.25 mgInterferon β-1a/Fingolimod 0.5 mg
Started42643143500
Completed36939838600
Not completed57334900
Withdrew: Adverse event269900
Withdrew: Withdrawal by subject1191600
Withdrew: Administrative problems62700
Withdrew: Lack of efficacy33700
Withdrew: Abnormal laboratory value(s)46100
Withdrew: Abnormal test procedure result(s)43300
Withdrew: Lost to follow-up11400
Withdrew: Death20000
Withdrew: Protocol violation00200
Extension Phase of Study
Participant flow — Extension Phase of Study
MilestoneFingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a 30 µgInterferon β-1a/Fingolimod 1.25 mgInterferon β-1a/Fingolimod 0.5 mg
Started3303570176167
Received study drug3303560174167
Completed2452810123123
Not completed857605344
Withdrew: Subject did not receive study drug01020
Withdrew: Subject withdrew consent263101215
Withdrew: Adverse event21220197
Withdrew: Abnormal laboratory value(s)14130134
Withdrew: Unsatisfactory therapeutic effect137049
Withdrew: Lost to follow-up11023
Withdrew: Subject no longer requires study drug40002
Withdrew: Administrative problems30011
Withdrew: Abnormal test procedure result(s)01002
Withdrew: Protocol violation30000
Withdrew: Death00001

Outcome measures

PrimaryEstimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study

The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.

Time frame:
Baseline to Month 12
Reported as:
Number · Estimate relapses per year
Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study
Estimate relapses per yearFingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a µg/Fingolimod 1.25 or 0.5 mg
Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study0.203 (0.157 to 0.264)0.161 (0.122 to 0.212)0.331 (0.262 to 0.417)
SecondaryNumber of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study

The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.

Time frame:
Baseline to Month 12
Reported as:
Mean · T2 lesions
Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study
T2 lesionsFingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a µg/Fingolimod 1.25 or 0.5 mg
Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study1.6 ± 3.231.6 ± 3.162.6 ± 5.50
SecondaryPercentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study

The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.

Time frame:
Baseline to Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study
Percentage of participantsFingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a µg/Fingolimod 1.25 or 0.5 mg
Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study93.3 (90.92 to 95.77)94.1 (91.82 to 96.33)92.1 (89.45 to 94.66)
SecondaryEstimated Annualized Aggregate Relapse Rate (ARR) in the Core and Extension Phases of the Study

The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.

Time frame:
Month 0 to end of study (up to approximately 4.5 years)
Reported as:
Number · Estimated relapses per year
Estimated Annualized Aggregate Relapse Rate (ARR) in the Core and Extension Phases of the Study
Estimated relapses per yearFingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a µg/Fingolimod 1.25 or 0.5 mg
Month 12 to Month 24, n=330, 356, 3410.156 (0.114 to 0.214)0.182 (0.138 to 0.242)0.266 (0.207 to 0.341)
Month 24 to Month 36, n=287, 321, 2930.116 (0.079 to 0.169)0.110 (0.076 to 0.160)0.121 (0.084 to 0.176)
Month 36 to Month 48, n=267, 303, 271NA (NA to NA)NA (NA to NA)NA (NA to NA)
Month 48 to end of study, n=36, 38, 29NA (NA to NA)NA (NA to NA)NA (NA to NA)
Month 0 to end of study, n=420, 429, 4310.192 (0.160 to 0.229)0.166 (0.139 to 0.199)0.271 (0.230 to 0.318)
SecondaryNumber of New or Newly Enlarged T2 Lesions in the Extension Phase of the Study

The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.

Time frame:
Month 12 to end of study (up to approximately 3.5 years)
Reported as:
Mean · T2 lesions
Number of New or Newly Enlarged T2 Lesions in the Extension Phase of the Study
T2 lesionsFingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a µg/Fingolimod 1.25 or 0.5 mg
Month 12 to Month 241.08 ± 2.6440.87 ± 1.6240.97 ± 1.923
Month 24 to Month 36, n=255, 289, 2581.40 ± 3.4181.04 ± 4.4080.72 ± 1.733
Month 36 to Month 48, n=36, 34, 350.97 ± 1.6820.59 ± 1.4380.49 ± 1.483
Last MRI scan to end of study, n=275, 309, 2901.75 ± 7.2480.86 ± 2.6741.03 ± 4.350
SecondaryPercentage of Participants Free of 3-month and 6-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Extension Phase of the Study

The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.

Time frame:
Baseline to end of study (up to approximately 4.5 years)
Reported as:
Number · Percentage of participants
Percentage of Participants Free of 3-month and 6-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Extension Phase of the Study
Percentage of participantsFingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a µg/Fingolimod 1.25 or 0.5 mg
Free of 3-month progression67.01 (57.26 to 95.77)71.28 (63.69 to 78.87)73.40 (68.56 to 78.23)
Free of 6-month progression79.54 (75.07 to 84.00)79.76 (75.53 to 83.98)81.61 (77.39 to 85.83)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
COR FTY720 1.25 mg—45/420 (10.7%)310/420 (73.8%)
COR FTY720 0.5 mg—30/429 (7%)302/429 (70.4%)
COR Interferon Beta-1a—25/431 (5.8%)359/431 (83.3%)
EXT FTY720 1.25 mg—77/504 (15.3%)446/504 (88.5%)
EXT FTY720 0.5 mg—76/523 (14.5%)439/523 (83.9%)
Most frequent serious events
Showing 10 of 221
Most frequent serious events
EventCOR FTY720 1.25 mgCOR FTY720 0.5 mgCOR Interferon Beta-1aEXT FTY720 1.25 mgEXT FTY720 0.5 mg
BradycardiaCardiac disorders8/4201/4290/4313/5041/523
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/4202/4290/4314/5047/523
Multiple sclerosis relapseNervous system disorders0/4201/4291/4314/5046/523
VertigoEar and labyrinth disorders0/4200/4291/4314/5040/523
Herpes zosterInfections and infestations1/4200/4290/4314/5041/523
CholelithiasisHepatobiliary disorders0/4201/4291/4310/5044/523
Atrioventricular block second degreeCardiac disorders3/4201/4290/4312/5040/523
LymphopeniaBlood and lymphatic system disorders1/4200/4290/4313/5041/523
PneumoniaInfections and infestations0/4200/4290/4313/5041/523
Atrioventricular block first degreeCardiac disorders2/4201/4290/4311/5040/523
Most frequent other events
Showing 10 of 33
Most frequent other events
EventCOR FTY720 1.25 mgCOR FTY720 0.5 mgCOR Interferon Beta-1aEXT FTY720 1.25 mgEXT FTY720 0.5 mg
Influenza like illnessGeneral disorders15/42015/429158/43124/50418/523
NasopharyngitisInfections and infestations93/42088/42988/431158/504162/523
HeadacheNervous system disorders96/42099/42988/43186/504107/523
LymphopeniaBlood and lymphatic system disorders3/4201/4290/431108/50477/523
PyrexiaGeneral disorders14/42018/42976/43133/50430/523
Upper respiratory tract infectionInfections and infestations36/42031/42927/43175/50459/523
FatigueGeneral disorders60/42044/42945/43139/50440/523
Lymphocyte count decreasedInvestigations1/4202/4290/43172/50442/523
Back painMusculoskeletal and connective tissue disorders27/42026/42923/43160/50453/523
Urinary tract infectionInfections and infestations24/42026/42921/43149/50458/523

Baseline characteristics

Age, Continuous
Age, Continuous(years)Fingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a 30 µgInterferon β-1a/Fingolimod 1.25 mgInterferon β-1a/Fingolimod 0.5 mgTotal
Mean35.8 ± 8.3936.7 ± 8.8136.0 ± 8.29NA ± NANA ± NA36.2 ± 8.50
Age, Continuous
Age, Continuous(Years)Fingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a 30 µgInterferon β-1a/Fingolimod 1.25 mgInterferon β-1a/Fingolimod 0.5 mgTotal
Mean35.5 ± 8.4236.5 ± 8.67NA ± NA36.1 ± 8.1136.1 ± 8.5936.0 ± 8.48
Age, Customized
Age, Customized(Participants)Fingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a 30 µgInterferon β-1a/Fingolimod 1.25 mgInterferon β-1a/Fingolimod 0.5 mgTotal
< 18000NANA0
18-30125117113NANA355
31-40160150185NANA495
41-55141164137NANA442
> 55000NANA0
Age, Customized
Age, Customized(Participants)Fingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a 30 µgInterferon β-1a/Fingolimod 1.25 mgInterferon β-1a/Fingolimod 0.5 mgTotal
< 1800NA000
18-3010098NA3948285
31-40122127NA8362394
41-55108131NA5257348
>5500NA000
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a 30 µgInterferon β-1a/Fingolimod 1.25 mgInterferon β-1a/Fingolimod 0.5 mgTotal
Female293282295NANANA
Male133149140NANANA
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Fingolimod 1.25 mgFingolimod 0.5 mgInterferon β-1a 30 µgInterferon β-1a/Fingolimod 1.25 mgInterferon β-1a/Fingolimod 0.5 mgTotal
Female227235NA114109685
Male103121NA6058342
08

Study locations

170 sites
  • North Central Neurology Associates, PC, 1809 Kress Street
    Cullman, Alabama 35058, United States
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • The Neurology Center, 3907 Waring Road, Suite 3
    Oceanside, California 92056, United States
  • Associated Neurologists, PC, 69 Sand Pit Road, Suite 300
    Danbury, Connecticut 06810, United States
  • Associated Neurologists of Southern CT, PC, 75 Kings Highway Cutoff
    Fairfield, Connecticut 06824, United States
  • Yale University Multiple Sclerosis Center
    New Haven, Connecticut 06510, United States
  • University of Florida Health Science Center
    Jacksonville, Florida 32209, United States
  • Neurology Associates, PA, 301 N. Maitland Avenue, Suite A1
    Maitland, Florida 32751, United States
  • University of Miami, Department of Neurology
    Miami, Florida 33136, United States
  • Neurological Associates
    Pompano Beach, Florida 33060, United States
  • Roskamp Institute, 2040 Whitfield Ave.
    Sarasota, Florida 34243, United States
  • AMO Corporation
    Tallahassee, Florida 32308, United States
  • Axiom Clinical Research of Florida, 2919 Swann Avenue, Suite 401
    Tampa, Florida 33609, United States
  • University of South Florida, Department of Neurology
    Tampa, Florida 33612, United States
  • The MS Center of Vero Beach
    Vero Beach, Florida 32960, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Mid America Neuroscience Institute, 8550 Marshall Drive, Suite 100
    Lenexa, Kansas 66214, United States
  • University Physician Group, #1 Barnes-Jewish Hospital Plaza, Suite 16304
    Saint Louis, Missouri 63110, United States
  • Neuroscience and Spine Center
    Charlotte, North Carolina 28207, United States
  • Raleigh Neurology Associates, 1540 Sunday Drive
    Raleigh, North Carolina 27607, United States
  • Neurology & Neuroscience Associates, Inc
    Akron, Ohio 44302, United States
  • Northern Ohio Neuroscience, LLC
    Bellevue, Ohio 44811, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Neurology
    Tualatin, Oregon 97062, United States
  • University of Pittsburgh, Department of Neurology
    Pittsburgh, Pennsylvania 15213, United States
  • Absher Neurology, 274-A Commonwealth Drive
    Greenville, South Carolina 29615, United States
  • Mountain Empire Neurological Associates, PC, 3183 West State Street, Suite 1201
    Bristol, Tennessee 37620, United States
  • Advanced Neurosciences Institute
    Franklin, Tennessee 37064, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Private Practice, 3815 23rd Street
    Lubbock, Texas 79410, United States
  • Integra Clinical Research, 4242 Medical Drive, Suite 6100
    San Antonio, Texas 78229, United States
  • Swedish Neuroscience Institute
    Seattle, Washington 98122, United States
  • Rockwood Clinic, P.S.
    Spokane, Washington 99202, United States
  • West Virginia University Health Associates
    Morgantown, West Virginia 26506, United States
  • Center for Neurological Disorders - Aurora St. Luke's Med Center
    Milwaukee, Wisconsin 53215, United States
  • Ineba
    Guarda Vieja 4435, Capital Federal, Buenos Aires 1428, Argentina
  • Fundacion Rosarina de Neurorehabilitacion
    Rosario, Santa Fe 2000, Argentina
  • Instituto de Neurociencias de Rosario
    Rosario, Santa Fe 2000, Argentina
  • Hospital Italiano de Buenos Aires
    Buenos Aires, C118ACK, Argentina
  • Fundacion Lenox Cordoba
    Cordoba, 5000, Argentina
  • Hospital J. M. Ramos Mejia
    General Urquiza 609, Buenos Aires, C1221ADC, Argentina
  • FLENI
    Montaneses 2325, Buenos Aires, C1428AQK, Argentina
  • Strategic Health Evaluators
    Chatswood, New South Wales 2067, Australia
  • Royal Prince Alfred Hospital
    Department of Medicine, Level, Missenden R, Camperdown, New South Wales 2050, Australia
  • Liverpool Hospital, Neurology Department, Health Services Building, 4th Floor, Goulburn and Campbell Street
    Liverpool, New South Wales 2170, Australia
  • Gosford Private Hospital
    North Gosford, New South Wales 2250, Australia
  • St George Private Hospital
    Suite 7E, Level 5, South Street, Kogarah, New South Wales 2217, Australia
  • Box Hill Hopsital, Level 3, 16 Arnold Street
    Box Hill, Victoria 3128, Australia
  • Royal Melbourne Hospital
    Suite 30, Grattan St., Parkbville, Victoria 3050, Australia
  • Landesklinikum St. Poelten, Probst-Ruehrer-Str. 4
    St. Poelten, Sankt Poelten 3100, Austria
  • Landes-Narvenklinik Wagner-Jauregg
    Abteilung fuer Neurologie, Linz, A-4020, Austria
  • Universitätsklinik f. Neurologie Innsbruck
    Anichstrasse 35, Innsbruck, 6020, Austria
  • Landes-Nervenklinik Christian Doppler Klinik
    Ignaz Harrerstr. 79 , Salzburg, A-5020, Austria
  • Evangel.Krankenh./Wien-Waehring Außenstelle
    Vienna, 1010, Austria
  • Univ.-Klinik fuer Neurologie AKH
    Vienna, 1090, Austria
  • Cliniques Universitaires Saint Luc
    Avenue Hippocrate 10, Bruxelles, 1200, Belgium
  • UZ Brussel
    Laarbeeklaan 101, Brussels, 1090, Belgium
  • Nationaal Multiple Sclerose Centrum v.z.w
    Melsbroek, 1820, Belgium
  • Regionaal Ziekenhuis Sint-Trudo - Campus Sint-Jozef
    Sint-Truiden, 3800, Belgium
  • Hospital Sao Rafael
    Salvador, BA 41256 900, Brazil
  • Hospital das Clincas - UNICAMP
    Campinas, SP 13083-970, Brazil
  • Hospital das Clinicas da FMRPUSP
    Ribeirao Preto, SP 48000-900, Brazil
  • Irmandade da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, RS 90020-090, Brazil
  • Hospital dos Servidores do Estado
    Rio de Janeiro, RJ 20221-903, Brazil
  • Hospital Universitario Gaffree e Guinle
    Rio de Janeiro, RJ 20270-004, Brazil
  • Fraser Health MS Clinic, Burnaby Hospital, 3935 Kincaid Street
    Vancouver, British Columbia V56 2X6, Canada
  • UBC MS Research, 2211 Westbrook Mall
    Vancouver, British Columbia V6T 2B5, Canada
  • Nepean Medical Centre, 1 Centrepointe Drive, Suite 407
    Ottawa, Ontario K2G 6E2, Canada
  • St. Michael's Hospital, Chief, Division of Neurology, 30 Bond Street,Suite 3007 - Shuter Wing
    Toronto, Ontario M5B 1W8, Canada
  • Centre Hospitalier Universitaire de Sherbrooke, 3001 12th Avenue North
    Fleurimont, Quebec J1H 5N4, Canada
  • Charles Lemoyne Hospital
    Greenfield Park, Quebec J4V 2H1, Canada
  • CHUM - Hopital Notre-Dame
    Montreal, Quebec H2L 4M1, Canada
  • Montreal Neurological Institute, 3801 University Street
    Montreal, Quebec H3A 2B4, Canada
  • The Ottawa General Hospital, 501 Smyth Rd.
    Ottawa, K1H 8L6, Canada
  • Private Clinic, 48 Sidi Gaber St.
    Alexandria, Egypt
  • 35, Dokki St., Apt. 4
    Cairo, Egypt
  • Al Azhar University, 11 Talaat Harb St, Fourth Floor, Apt 18
    Cairo, Egypt
  • Private Clinic, 35 Dokki St., Apt. 4
    Cairo, Egypt
  • Private Clinic, 7 Batal Ahmed Abdelaziz St Abdeen
    Cairo, Egypt
  • Hopital La Timone Cpcet, Rue Jean Moulin
    Marseille, 13385, France
  • Hopital Central, 29 Avenue du Marechal de Lattre de Tassigny
    Nancy, 54035, France
  • Hôpital Pellegrin
    Place Amélie Raba Léon, Bordeaux Cedex, 33076, France
  • Hopital De Purpan
    Place du Dr. Baylac, Toulouse Cedex, 31059, France
  • Centre Hospitalier de Poissy, 10 rue du Champ Gaillard
    Poissy, 78303, France
  • Hoppital Pasteur, Archet II, 30 avenue de la Voie
    Romaine, 06602, France
  • Investigational Site
    Bamberg, 96049, Germany
  • Investigational Site
    Berlin, 10713, Germany
  • Investigational Site
    Berlin, 13439, Germany
  • Investigational Site
    Bremen, 28177, Germany
  • Investigational Site
    Buchholz, 21244, Germany
  • Investigational Site
    Dresden, 01307, Germany
  • Investigational Site
    Dusseldorf, 40225, Germany
  • Investigational Site
    Erbach/Odenwald, 64711, Germany
  • Investigational Site
    Essen, 45122, Germany
  • Investigational Site
    Freiburg, 79106, Germany
  • Investigational Site
    Greifswald, 17475, Germany
  • Investigational Site
    Hamburg, 66421, Germany
  • Investigational Site
    Hannover, 30623, Germany
  • Investigational Site
    Heidelberg, 69120, Germany
  • Investigational Site
    Hennigsdorf, 16761, Germany

Showing the first 100 of 170 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L; TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016 May;87(5):468-75. doi: 10.1136/jnnp-2015-310597. Epub 2015 Jun 25. PubMed 26111826 ↗
  • Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA; TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon beta-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12. PubMed 25876473 ↗
  • Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses. Adv Ther. 2014 Oct;31(10):1072-81. doi: 10.1007/s12325-014-0154-4. Epub 2014 Sep 23. PubMed 25245812 ↗
  • Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul;120(7):1432-9. doi: 10.1016/j.ophtha.2012.12.040. Epub 2013 Mar 24. PubMed 23531349 ↗
  • Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13. PubMed 21571593 ↗
  • Twiss J, Doward LC, McKenna SP, Eckert B. Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS). Health Qual Life Outcomes. 2010 Oct 11;8:117. doi: 10.1186/1477-7525-8-117. PubMed 20937112 ↗
  • Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. PubMed 20089954 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2006
First posted
Jun 21, 2006
Start
May 2006
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
May 16, 2011
Last update
Sep 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00340834
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Jun 21, 2006
Start date
May 2006
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
May 16, 2011
Last update
Sep 21, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmacuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion